A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Oct 2018 Results of a subgroup analysis assessing eficacy and safety of elagolix in a subgroup of women with both UF and adenomyosis, presented at the American Society for Reproductive Medicine Scientific Congress 2018.
05 Oct 2018 Results published in the Obstetrics and Gynecology
23 May 2018 Results asessing effect of elagolox on quality of life presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com